NovoCure Q1 2024 Adj EPS $(0.36) Beats $(0.42) Estimate, Sales $138.50M Beat $131.45M Estimate
NovoCure Q1 2024 Adj EPS $(0.36) Beats $(0.42) Estimate, Sales $138.50M Beat $131.45M Estimate
NovoCure 2024 年第一季度經調整後每股收益 (0.36) 超過預期 (0.42) 美元,銷售額爲1.385億美元,超過預期的1.3145億美元
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 14.29 percent. The company reported quarterly sales of $138.50 million which beat the analyst consensus estimate of $131.45 million by 5.37 percent. This is a 13.36 percent increase over sales of $122.18 million the same period last year.
NovoCure(納斯達克股票代碼:NVCR)公佈的季度虧損爲每股0.36美元,比分析師普遍預期的0.42美元(0.42美元)高出14.29%。該公司公佈的季度銷售額爲1.385億美元,比分析師普遍預期的1.3145億美元高出5.37%。這比去年同期的1.2218億美元的銷售額增長了13.36%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。